嚴重複合型免疫力缺乏症(SCID)診斷的全球市場(2021年∼2028年)

帶動全球嚴重複合型免疫力缺乏症(SCID)診斷市場的要素，是嚴重複合型免疫力缺乏症(SCID)的發生率增加，和診斷方法的認識度提高。但，預計診斷的延遲和不當診斷，妨礙市場成長。

還有全球市場，北美地區佔最大的佔有率。嚴重複合型免疫力缺乏症(SCID)的發生率增加和診斷方法的改善，預計該地區的市場處於優勢。美國疾病管理預防中心的檢驗部，確立利用乾燥血痕的SCID的檢驗項目與標準物質，以擴大全美的篩檢為目標。

本報告提供全球嚴重複合型免疫力缺乏症(SCID)診斷市場的相關調查，市場規模，機會和影響，促進及阻礙因素，COVID-19的影響，各疾病類型、檢驗類型、終端用戶、地區的市場分析，競爭情形，主要企業的簡介等資訊。

目錄

第1章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場調查手法和範圍

• 調查手法
• 調查的目的和調查範圍

第2章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-市場定義和概要

第3章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-摘要整理

• 各疾病類型的市場明細
• 各檢驗類型的市場明細
• 各終端用戶市場明細
• 各地區的市場明細

第4章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-市場動態

• 影響市場的要素
  • 促進因素
  • 阻礙因素
  • 市場機會
  • 影響分析

第5章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-產業分析

• 波特的五力分析
• 流行病學分析
• 供應鏈分析
• 價格分析
• 法規分析
• 償付分析
• 未滿足需求

第6章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-COVID-19分析

• 市場上的COVID-19分析
  • COVID-19前的市場情境
  • 目前市場情境
  • COVID-19後或今後情境
• COVID-19的價格趨勢
• 需求與供給的頻譜
• 大流行時的市場相關的政府舉措
• 製造商策略性舉措
• 結論

第7章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-各疾病類型

• 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
• X連鎖SCID
• ADA-SCID
• 其他

第8章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-各檢驗類型

• 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
• TREC
• 血液常規檢查(CBC)
• 遺傳基因檢驗
• 生物化學的實驗

第9章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-各終端用戶

• 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
• 醫院
• 門診病人手術中心
• 其他

第10章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-各地區

• 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
• 北美
• 歐洲
• 南美
• 亞太地區
• 中東和非洲

第11章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-競爭情形

• 主要的發展與策略
• 企業佔有率分析
• 產品的基準

第12章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-企業簡介

• Archimedlife
  • 企業概要
  • 產品系列、概要
  • 要點
  • 財務概要
• PerkinElmer
• Health Research, Inc.
• Winfertility
• Portea Medical
• LaCAR MDx
• Labsystems Diagnostics
• Devyser
• Revcovi
• Leadiant Biosciences, Inc.

第13章 全球嚴重複合型免疫力缺乏症(SCID)診斷市場-DataM

• 附錄
• 關於本公司、服務
• 諮詢方式

Market Overview

The global severe combined immunodeficiency (SCID) diagnosis market size was valued at US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).

SCID (severe combined immunodeficiency) is a group of rare disorders which occurs by mutations in genes involved in the development and function of infection-fighting immune cells. A detailed medical history and physical examination of the child are usually used to diagnose severe combined immunodeficiency (SCID). To help confirm the diagnosis, additional blood tests, including a total blood cell count, may be ordered.

Market Dynamics

The factors driving the global severe combined immunodeficiency (SCID) diagnosis market is increasing incidence of severe combined immunodeficiency (SCID) disorder and the increased awareness of diagnosis procedures.

Increasing incidence of severe combined immunodeficiency (SCID) disorder is estimated to drive the market

Adenosine deaminase deficiency is extremely rare, affecting just around 1 in 200,000 to 1,000,000 infants worldwide. This disorder causes about 15% of SCID cases. SCID (severe combined immunodeficiency) is a rare genetic condition that causes life-threatening immune system abnormalities. It's a form of primary immunological symptom. Every year, about 1 in 58,000 newborns in the United States is born with SCID. Severe combined immunodeficiency is an inherited primary immunodeficiency disease (PIDD) that often manifests in childhood and causes substantial immune insufficiency, resulting in a weakened immune system that cannot fight off even minor infections. It is thought to be the most serious of the PIDDs.

SCID is caused by genetic mutations that alter T cell activity. B cells and NK cells may be altered depending on the type of SCID. These cells play a vital part in the immune system's fight against infection-causing bacteria, viruses, and fungus. Without therapy with hematopoietic stem cell transplantation, affected newborns generally die during the first year of life. (HSCT) Newborn screening for SCID can identify infants before they become ill, allowing for a faster transplant process and better post-transplant results. Transplantation performed within the first three months of life has the best chance of success. SCID comes in a variety of forms. The most prevalent kind is caused by a mutation in an X chromosome gene that only affects males. Women may have the disorder, but they also have a normal X chromosome. Since the advent of screening for SCID, recessive versions of the condition, which can afflict both males and girls, have become more common. A lack of the enzyme adenosine deaminase and a range of other genetic abnormalities produce other kinds of SCID. Infants with SCID are susceptible to common diseases observed in healthy babies. Still, they are also more sensitive to infections caused by organisms or live vaccinations, which are normally not dangerous to children with normal immunity.

Increased awareness of diagnostic procedures is estimated to drive the global severe combined immunodeficiency (SCID) diagnosis market

A detailed medical history and physical examination of the child are usually used to diagnose severe combined immunodeficiency (SCID). A total blood cell count and other blood tests may be conducted to help confirm the diagnosis. Newborn screening is very helpful in detecting SCID before symptoms appear. SCID is now being tested as part of a required newborn screening process in a rising number of states. It's especially crucial to get screened because many infants with SCID don't exhibit any symptoms until they catch an infection. Pathologists examine B- and T-lymphocyte counts in blood samples from patients suspected of having SCID. In addition to low levels or the absence of germ-fighting antibodies, the samples show a drop in lymphocyte numbers. A timely diagnosis of SCID can save a child's life, although this is extremely rare because differential blood count testing in newborns is not routinely performed.

SCID does not normally show up clinically right after a baby is born. This is because babies with SCID thrive on the acquired immunity from their mother's antibodies, at least for the first several weeks. However, due to a lack of immune response, newborns are impacted even by weakened bacteria in vaccines such as polio, rotavirus, chickenpox, BCG, and others over time. SCID diagnosis is usually made when the newborns reach the age of four to six months after the symptoms have shown. When there is a possible danger due to a family history of immunodeficiency, the earliest intervention could be DNA sequencing of the foetus for any relevant gene alterations. SCID can be detected early in pregnancy, giving the kid plenty of time to be treated after birth. New-born screening is the next best option. It is possible to collect a blood sample at birth to count T-cells and B-cells and analyse their functions. For a more thorough diagnosis, postnatal DNA testing can be used.

Delayed and improper diagnosis is estimated to hamper the global severe combined immunodeficiency (SCID) diagnosis market

On the other hand, a significant infection can be the first sign that something is amiss, resulting in a quick worsening in the baby's state, necessitating an urgent admission to the hospital and sometimes to an intensive care unit. SCID may be suspected due to normal testing, mainly due to a low lymphocyte count in the blood. As the possibility of SCID is recognized an infant is referred to a specialist immunology centre. Further examinations will be required to confirm the diagnosis and, later, to determine the type of SCID. SCID patients are particularly susceptible to severe and repeated infections, and they do not survive childhood unless they are given immune-rebuilding therapy.

Due to the lack of a documented family history, the lack of distinguishing physical traits, and infections are common in the general pediatric population. Unfortunately, medical providers only consider the potential of a flaw in host defenses after a patient has experienced a series of illnesses, many of which are serious. Unfortunately, newborns with SCID who do not have an affected older sibling or other known affected family are frequently diagnosed until after many infections have occurred. These infections can be fatal in certain situations, but they always have a considerable impact on immediate medical care, family hardship, and long-term morbidity.

COVID-19 Impact Analysis

COVID-19 has affected the healthcare industry moderately. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. The diagnosis tests were reduced during the pandemic due to the fear of COVID. This has moderately affected the global severe combined immunodeficiency (SCID) diagnosis market due to limitations to avoid transmission of COVID.

Segment Analysis

Based on disease type, the X-linked SCID segment is expected to dominate the global severe combined immunodeficiency (SCID) diagnosis market

SCID (X-linked severe combined immunodeficiency) is an inherited immune system illness that affects virtually exclusively men. Because they lack the required immune cells to fight off some bacteria, viruses, and fungi, boys with X-linked SCID are prone to recurring and persistent illnesses. The most frequent form of SCID is X-linked SCID. Although the actual incidence is unknown, the illness is thought to affect at least one out of every 50,000 to 100,000 babies.

According to retrospective multicenter investigations in North America and Europe, X-SCID accounts for 40 to 50 percent of all SCID diagnoses. According to findings from a newborn screening (NBS) research including three million live births in NBS programs across the United States, roughly 22% of newborns with conventional SCID have the X-linked type. This lower figure was backed up by research conducted by NBS in California, which found that 29 percent of neonates diagnosed with SCID had the X-related variant among 2.5 million babies tested. Except in locations with a founder effect or a significant incidence of consanguinity, X-SCID remains more common than any other genotype.

Geographical Analysis

North America region accounted for the largest market share in the global severe combined immunodeficiency (SCID) diagnosis market

The market in this region is assumed to dominate due to the increasing incidence of severe combined immunodeficiency (SCID) and better diagnosis procedures.

Around 1 in 58,000 babies are born with SCID in the U.S. each year. Newborn screening detects congenital diseases such as SCID in newborns. In the United States, about 4 million infants are checked for various disorders each year, and SCID is currently screened in 45 states, the District of Columbia, and Puerto Rico. The Division of Laboratory Sciences at the Centers for Disease Control and Prevention has established laboratory tests and reference materials for SCID utilising dried bloodspots and is aiming to expand screening across the country.

Competitive Landscape

Some major key players in the global severe combined immunodeficiency (SCID) diagnosis market are Archimedlife, PerkinElmer, Health Research, Inc., Winfertility, Portea Medical , LaCAR MDx, Labsystems Diagnostics, Devyser, Revcovi and Leadiant Biosciences, Inc.

The global severe combined immunodeficiency (SCID) diagnosis market is moderately competitive with the limited disorder diagnosis and procedures available.

Archimedlife

• Overview: Archimedlife is a high-tech firm specialising in laboratory diagnosis and research, with an emphasis on rare diseases and newborn screening. They make tailored diagnostics more accessible for anything from inborn metabolic errors to oncology.The company offers a wide range of services, from standard diagnostics to clinical research, as well as biochemical and genetic testing. And are committed to the development of breakthrough laboratory tests that provide quick access to actionable health information.

• Product Portfolio: The company comprises of clinical mass spectrometry, laboratory diagnostic services, IVD, GLP / GMP, biochemistry, Dried Blood Spot cards, Rare Diseases, metabolic disorders, clinical research, development of novel diagnostic assays, Newborn Screening, Baby Health Check, genetic testing, biomarker studies, metabolomics, Lysosomal Storage Disorders, Next-Generation sequencing , and translational research

• Key Development: On September 24th 2019, Blueprint Genetics and Archimedlife Medical Laboratory, a rare disease diagnostics company, have joined to offer biochemical testing for rare diseases in North America.

Why Purchase the Report?

• Visualize the composition of the global severe combined immunodeficiency (SCID) diagnosis market Segmentation by Disease Type, by Test type and End-User highlighting the key commercial assets and players.

• Identify commercial opportunities in global severe combined immunodeficiency (SCID) diagnosis market by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of global severe combined immunodeficiency (SCID) diagnosis market - level 4/5 segmentation.

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for the key product of all major market players

The global severe combined immunodeficiency (SCID) diagnosis market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers

Market Segmentation

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By Disease Type

• X-linked SCID
• ADA-SCID
• Others

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By Test type

• TREC
• Complete blood count (CBC)
• Genetic Test
• Biochemical Test

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By End-User

• Hospitals
• Ambulatory Surgical Centers
• Other

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By Region

• North America
• Europe
• South America
• Asia Pacific
• Middle East and Africa

Table of Contents

1. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - Market Definition and Overview

3. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - Executive Summary

• 3.1. Market Snippet by Disease Type
• 3.2. Market Snippet by Test type
• 3.3. Market Snippet by End-User
• 3.4. Market Snippet by Region

4. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market -Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing incidence of severe combined immunodeficiency (SCID) disorder
    • 4.1.1.2. Increased awareness of diagnosis procedures
  • 4.1.2. Restraints:
    • 4.1.2.1. Delayed and improper diagnosis
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis
• 5.5. Regulatory Analysis
• 5.6. Reimbursement Analysis
• 5.7. Unmet Needs

6. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By Disease Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 7.1.2. Market Attractiveness Index, By Disease Type Segment
• 7.2. X-linked SCID
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Mn, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 7.3. ADA-SCID
• 7.4. Other

8. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By Test type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test type
  • 8.1.2. Market Attractiveness Index, By Test type
• 8.2. TREC*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 8.3. Complete blood count (CBC)
• 8.4. Genetic Test
• 8.5. Biochemical Test

9. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 9.1.2. Market Attractiveness Index, By End-User Segment
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
• 9.3. Ambulatory Surgical Centers
• 9.4. Other

10. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test type
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test type
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test type
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test type
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - Company Profiles

• 12.1. Archimedlife*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. PerkinElmer
• 12.3. Health Research, Inc.
• 12.4. Winfertility
• 12.5. Portea Medical
• 12.6. LaCAR MDx
• 12.7. Labsystems Diagnostics
• 12.8. Devyser
• 12.9. Revcovi
• 12.10. Leadiant Biosciences, Inc. (*LIST NOT EXHAUSTIVE)

13. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us